Radiopharmaceuticals and Theranostics: The High Road Ahead

ConclusionRadiopharmaceuticals are poised to play a transformative role in the future of precision oncology.Their ability to combine diagnostic accuracy with targeted therapy aligns well with emerging trends in personalized medicine.Rising cancer prevalence globally, regulatory and payer preferences for safer, more tolerable therapies and technological advancements in targeting and delivery means that multidisciplinary collaboration, infrastructure investments, and innovative clinical models are urgently needed.Achieving this potential on a global scale will require concerted efforts to overcome key operational, regulatory, and perceptual barriers.Stakeholders including policymakers, pharmaceutical developers, contract research organizations (CROs), academic medical centers, and payers must align to build scalable, patientcentered radiopharmaceutical programs.With a clear roadmap and collaborative strategy, radiopharmaceuticals can evolve from niche interventions into mainstream oncologic tools with meaningful global impact.